According to Arrowhead Pharmaceuticals 's latest financial reports the company's total liabilities are $0.45 B. A companyโs total liabilities is the sum of all current and non-current debts and obligations.
Year | Total liabilities | Change |
---|---|---|
2023-09-30 | $0.47 B | 74.85% |
2022-09-30 | $0.27 B | -9.2% |
2021-09-30 | $0.30 B | 396.21% |
2020-09-30 | $60.72 M | -42.61% |
2019-09-30 | $0.10 B | 546.4% |
2018-09-30 | $16.36 M | -29.31% |
2017-09-30 | $23.15 M | -30.16% |
2016-09-30 | $33.15 M | 46.39% |
2015-09-30 | $22.64 M | 34.55% |
2014-09-30 | $16.83 M | 45.16% |
2013-09-30 | $11.59 M | 50.21% |
2012-09-30 | $7.71 M | 132.19% |
2011-09-30 | $3.32 M | -22.26% |
2010-09-30 | $4.27 M | 50.35% |
2009-09-30 | $2.84 M | -42.57% |
2008-09-30 | $4.95 M | 45.83% |
2007-09-30 | $3.39 M | 16.3% |
2006-09-30 | $2.92 M | 185.16% |
2005-09-30 | $1.02 M | 48.48% |
2004-09-30 | $0.68 M | 617.11% |
2003-09-30 | $0.09 M | -94.04% |
2002-09-30 | $1.61 M | 19.5% |
2001-09-30 | $1.35 M |
Company | Total liabilities | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $98.78 B | 21,727.25% | ๐บ๐ธ USA |
Moderna
MRNA | $4.57 B | 910.23% | ๐บ๐ธ USA |
Ligand Pharmaceuticals LGND | $86.3 M | -80.93% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | $4.05 B | 795.00% | ๐บ๐ธ USA |
Inovio Pharmaceuticals INO | $53.6 M | -88.16% | ๐บ๐ธ USA |